| Trial ID: | L7172 |
| Source ID: | NCT02084654
|
| Associated Drug: |
Exenatide 5 And 10 Mcg 2 Times A Day
|
| Title: |
Exenatide and Weight Loss for Diabetes Prevention
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Pre Diabetes|Insulin Resistance
|
| Interventions: |
DRUG: Exenatide 5 and 10 mcg 2 times a day|DRUG: placebo
|
| Outcome Measures: |
Primary: First-phase insulin response, measured using ivgtt, 7 months | Secondary: glucose lowering effect, measured by fasting and 2 hr plasma glucose during OGTT, 8 months | Other: insulin-mediated glucose uptake (insulin sensitivity), This is measured by the SSPG, or modified insulin-suppression test. it is a "gold standard" measurement of insulin-mediated glucose uptake, and is precise and quantitative., 8 months
|
| Sponsor/Collaborators: |
Sponsor: Stanford University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
66
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose:
|
| Start Date: |
2007-11
|
| Completion Date: |
2013-02
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-04
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT02084654
|
